Qualigen Therapeutics (AIXC) and The Competition Head-To-Head Review

Qualigen Therapeutics (NASDAQ:AIXC) is one of 450 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare Qualigen Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.

Earnings & Valuation

This table compares Qualigen Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Qualigen Therapeutics	N/A	-$6.26 million	-0.15
Qualigen Therapeutics Competitors	$432.51 million	-$67.33 million	-12.08

Qualigen Therapeutics’ rivals have higher revenue, but lower earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for Qualigen Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
Qualigen Therapeutics Competitors	4919	9984	15999	377	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 61.35%. Given Qualigen Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Qualigen Therapeutics has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 39.2% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 13.5% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Qualigen Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-52.57%
Qualigen Therapeutics Competitors	-2,683.22%	-366.86%	-43.27%

Volatility & Risk

Qualigen Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics’ rivals have a beta of 5.82, meaning that their average share price is 482% more volatile than the S&P 500.

Summary

Qualigen Therapeutics rivals beat Qualigen Therapeutics on 9 of the 13 factors compared.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.